Hansa Medical’s rights issue oversubscribed
Hansa Medical’s rights issue with preferential rights has been subscribed at 137 percent of which 99 percent was subscribed through preferential rights. The rights issue comprises 3.7 million shares at SEK 10 per share, which brings SEK 37 million to the company before issue expenses. The capital will be used for Phase II-studies with the drug candidate IdeS during 2014 and 2015.
An extraordinary general meeting held on March 5, 2014, resolved to carry through a rights issue of at the most 3 704 229 shares with preferential rights at SEK 10 per share. The subscription period for the offer was between March 25 and April 8.
In total 3 658 875 shares have been subscribed for with preferential rights, which corresponds to 99 percent of the number of shares issued. In addition, 1 417 323 shares were subscribed for without preferential rights, corresponding to 38 percent of the number of shares issued. Shares being subscribed for without preferential rights will be assigned according to the principles described in the prospectus published on March 19, 2014. No rights issue guarantee will be applied due to the oversubscription of the rights issue.
The rights issue increases the number of Hansa Medical shares with 3 704 229 shares to a total amount of 25 929 603 shares. Following the rights issue, the share capital amounts to 25 929 603.
Paid subscribed shares, subscribed with preferential rights, is traded under short name HMED BTA 1 at NASDAQ OMX First North until the end of April when they will be converted to shares. Paid subscribed shares, subscribed without preferential rights, will be traded under short name HMED BTA 2 starting at the end of next week.
For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO Hansa Medical AB (publ)
Mobile: 46 707 17 54 77
E-mail: emanuel.bjorne@hansamedical.com
www.hansamedical.com
Hansa Medical pursues clinical development and commercialization of innovative pharmaceuticals and diagnostic methods for the benefit of patients with serious and rare inflammatory diseases. The portfolio includes a marketed diagnostic product, a drug candidate in clinical development, and a preclinical research project. Major shareholders are Bo Håkansson via Farstorps Gård AB, and Nexttobe AB. Hansa Medical is listed on NASDAQ OMX First North (HMED) and Remium Nordic AB is the company’s Certified Adviser. The information in this press release is such information that Hansa Medical AB (publ) is obliged to disclose under the Securities Market Act and/or the Financial Instruments Trading Act. The information was made public on April 11, 2014 at 08:30 CET.
Tags:
